Literature DB >> 6684317

Adrenergic-cholinergic balance and the treatment of affective disorders.

D S Janowsky, S C Risch, J C Gillin.   

Abstract

Centrally acting cholinomimetic drugs cause anergia, behavioral inhibition and depression. Centrally acting cholinomimetic drugs have antimanic properties. Combinations of acetylcholine precursors and centrally active cholinomimetic agents may cause augmented muscarinic effects, as may a combination of an antiadrenergic and cholinomimetic drugs. Centrally active anticholinergic agents may exert antidepressant effects. Affective disorder patients may show hyperreactivity to cholinomimetic agents, a phenomena which may have diagnostic significance.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6684317     DOI： 10.1016/0278-5846(83)90119-7

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN： 0278-5846            Impact factor:   5.067


  9 in total

1.  Scopolamine produces larger antidepressant and antianxiety effects in women than in men.

Authors:  Maura L Furey; Ashish Khanna; Elana M Hoffman; Wayne C Drevets
Journal:  Neuropsychopharmacology       Date:  2010-08-25       Impact factor: 7.853

2.  Mesolimbic effects of the antidepressant fluoxetine in Holtzman rats, a genetic strain with increased vulnerability to stress.

Authors:  Eimeira Padilla; Jason Shumake; Douglas W Barrett; Eva C Sheridan; F Gonzalez-Lima
Journal:  Brain Res       Date:  2011-03-02       Impact factor: 3.252

3.  Fluoxetine alleviates behavioral depression while decreasing acetylcholine release in the nucleus accumbens shell.

Authors:  David T Chau; Pedro V Rada; Kay Kim; Rebecca A Kosloff; Bartley G Hoebel
Journal:  Neuropsychopharmacology       Date:  2011-04-27       Impact factor: 7.853

4.  Promoter IV-BDNF deficiency disturbs cholinergic gene expression of CHRNA5, CHRM2, and CHRM5: effects of drug and environmental treatments.

Authors:  Kazuko Sakata; Abigail E Overacre
Journal:  J Neurochem       Date:  2017-08-16       Impact factor: 5.372

Review 5.  Molecules and circuits involved in nicotine addiction: The many faces of smoking.

Authors:  Marina R Picciotto; Yann S Mineur
Journal:  Neuropharmacology       Date:  2013-04-28       Impact factor: 5.250

6.  Multivariate permutation analysis associates multiple polymorphisms with subphenotypes of major depression.

Authors:  M K Hahn; J U Blackford; K Haman; M Mazei-Robison; B A English; H C Prasad; A Steele; L Hazelwood; H M Fentress; R Myers; R D Blakely; E Sanders-Bush; R Shelton
Journal:  Genes Brain Behav       Date:  2007-12-06       Impact factor: 3.449

7.  Down-regulation of cholinergic signaling in the habenula induces anhedonia-like behavior.

Authors:  Seungrie Han; Soo Hyun Yang; Jin Yong Kim; Seojung Mo; Esther Yang; Ki Myung Song; Byung-Joo Ham; Naguib Mechawar; Gustavo Turecki; Hyun Woo Lee; Hyun Kim
Journal:  Sci Rep       Date:  2017-04-18       Impact factor: 4.379

Review 8.  Cholinergic regulation of mood: from basic and clinical studies to emerging therapeutics.

Authors:  Stephanie C Dulawa; David S Janowsky
Journal:  Mol Psychiatry       Date:  2018-08-17       Impact factor: 15.992

Review 9.  Repurposing Cholinesterase Inhibitors as Antidepressants? Dose and Stress-Sensitivity May Be Critical to Opening Possibilities.

Authors:  Paul J Fitzgerald; Pho J Hale; Anjesh Ghimire; Brendon O Watson
Journal:  Front Behav Neurosci       Date:  2021-01-14       Impact factor: 3.558
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.